Children's Bipolar Network Treatment Trial I
Launched by UNIVERSITY OF CALIFORNIA, LOS ANGELES · Jun 15, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Children's Bipolar Network Treatment Trial I is a study designed to better understand and treat children and teenagers aged 9 to 19 who have bipolar disorder and related conditions. The trial aims to accurately identify these young patients and explore factors that may influence their treatment outcomes over a year, such as mood changes and specific blood markers. Participants will go through a thorough screening process, which includes an interview and a blood test, to help with diagnosis. Families will also be involved in follow-up visits that include various assessments to track the youth's progress.
To be eligible for this study, participants must be between 9 and 19 years old and have a diagnosis of bipolar disorder or a related condition confirmed by the study team. It’s important that they can communicate in English, along with a caregiver who will be involved in their ongoing assessment and treatment. Participants can expect to receive personalized care, including medication management and psychosocial support, while contributing to research that aims to improve treatment methods for bipolar disorders in children and adolescents.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Youth 9-19 years old
- • Youth diagnosed with Bipolar disorder (I, II, Other Specified) or Cyclothymic Disorder by the study team during the diagnostic interview screening
- • Youth is able to read and communicate in English to the degree necessary to be able to assent and participate (with help) in their treatment and assessments appropriate for ages 9 and up
- • Youth has a caregiver able to participate in ongoing basis in assessment and treatment
- • The participating caregiver can reliably read and communicate in English for purposes of study consenting, assessment, and treatment, unless preferred language translation services are regularly available.
- Exclusion Criteria:
- • Youth has DSM-5 diagnosis of autism spectrum disorder
- • Youth has DSM-5 diagnosis of substance or alcohol abuse with impairment within 3 mos.
- • Youth has a medical or psychiatric disorder that is life-threatening or requires immediate hospitalization or emergency medical or therapeutic treatment
- • Evidence of recent sexual or physical abuse of the youth by legally responsible caregivers
- • Evidence of recent intimate partner violence between caregivers responsible for the youth's care
About University Of California, Los Angeles
The University of California, Los Angeles (UCLA) is a prestigious academic institution renowned for its commitment to research and innovation in the biomedical field. As a clinical trial sponsor, UCLA leverages its cutting-edge facilities, expert faculty, and collaborative environment to advance medical knowledge and improve patient care. The university is dedicated to conducting rigorous clinical research that adheres to the highest ethical standards, aiming to translate scientific discoveries into effective therapies and interventions. Through its diverse array of clinical trials, UCLA seeks to address critical health challenges while fostering the development of future healthcare leaders.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Richmond, Virginia, United States
Los Angeles, California, United States
Aurora, Colorado, United States
Pittsburgh, Pennsylvania, United States
Patients applied
Trial Officials
David J Miklowitz, PhD
Principal Investigator
University of California, Los Angeles
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials